Robert Karr

Dr. Karr has broad experience in the drug discovery and development process, including discovery/preclinical research, IND preparation, interactions with the FDA, the design and conduct of clinical trials, and investor relations.

Prior to joining Antegrin, he served as President of Idera Pharmaceuticals (Cambridge, MA) from 2005-2007, and he continues to serve on Idera’s Board of Directors.

From 2005-2011, he was a Director of GTx, Inc., a biotechnology company based in Memphis, TN. From 2000-2004, he was a senior executive in Global Research and Development for Pfizer, where he served as Senior Vice President of Strategic Management from 2003-2004.

Prior to joining Pfizer, he served as Vice President of Research and Development Strategy for Warner-Lambert Company. From 1991-1999, he held roles of increasing responsibility in Discovery Research at G.D. Searle, including project leader, department leader, and co-interim leader of Discovery Research. Dr. Karr completed his internship and residency in internal medicine at Washington University School of Medicine and served as a faculty member at both the University of Iowa College of Medicine and Washington University School of Medicine.

He received his B.S. (Honors) from Southwestern University in 1971 and his M.D (with highest honors) from the University of Texas Medical Branch in 1975.

Robert Karr is the President & CEO at Arch Oncology. With a background in Biotechnology, Robert Karr has a rich history of leadership and innovation.Robert Karr studied MD unknown at The University of Texas Medical Branch. Explore their detailed professional journey, key connections, and contributions to the industry on our platform.